TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presented Fri 28 Aug · 11:00 CESTHot Line 1All Hot Line trials →

CARDIO-TTRansform

2026

A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 (Eplontersen) in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy

In 1,432 patients with transthyretin amyloid cardiomyopathy, eplontersen did not reduce cardiovascular death or recurrent cardiovascular events at 140 weeks compared with placebo.

Result

Efficacy: Composite of cardiovascular mortality and recurrent cardiovascular clinical events through week 140rate ratio 0.89 (95% CI 0.73-1.09) · P = 0.28

Below 1 favours eplontersen, above 1 favours placebo.

Event rates Eplontersen 381 vs placebo 392 events

Also reported: Serum transthyretin was suppressed through week 140. Without a background stabiliser fewer primary events with eplontersen (nominal significance); with one, no incremental effect.

Original publication
Subtopic
Cardiac amyloidosis
Design
Phase 3 double-blind, placebo-controlled RCT, 1:1, subcutaneous dosing every 4 weeks for up to 140 weeks on top of local standard of care (TTR stabilisers permitted), followed by a 20-week post-treatment period or open-label extension
Relevance
Practice-defining: a trial the field needs to know.
Source
Fontana M, Masri A, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2608510

Discussion & critique

The largest trial ever run in ATTR cardiomyopathy, and a negative one: transthyretin was knocked down as designed, but events did not follow. Fifty-seven percent were already taking a stabiliser, and the prespecified subgroup without one was nominally positive: a hypothesis about non-additive mechanisms, not a finding. The primary analysis counts recurrent events rather than time to first, which is the more generous framing and still did not reach significance.

Discussed in podcasts